// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Measurement of joint status in patients with hemophilia: a systematic review of the measurement properties of hemophilia‐specific joint examination scores

S. C. Gouw - European Association for Haemophilia and Allied Disorders (EAHAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

EXTH-47. THERAPEUTIC REVERSAL OF PRENATAL PONTINE ID1 SIGNALING IN DIPG

Xuhong Cao - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse intrinsic pontine glioma

Cannabidiol

TMIC-21. TARGETING INVADOPODIA TO BLOCK IONIZING RADIATION-INDUCED GLIOBLASTOMA CELL INVASION

Lisa Decotret - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Glioblastoma

N/A

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

Mario Campone - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High-Grade Gliomas

Dabrafenib Mesylate

SCIDOT-47. EFFECT OF ulRFE COGNATES EMULATING BIOACTIVE SUBSTANCES ON ANIMAL BEHAVIOR

Xavier Figueroa - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

GENE-27. MENINGIOMA RECURRENCE: ROLE OF M1/M2 TUMOUR-ASSOCIATED MACROPHAGE INFILTRATION

Dustin Proctor - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Meningiomas

N/A

ATIM-33. INTERIM RESULTS OF A PHASE II MULTI-CENTER STUDY OF ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192)

Shirley Ong - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Pembrolizumab

PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS

Brian Weiss - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary edema

Entrectinib

ATIM-12. AVELUMAB IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME-THE SEJ STUDY

Francois Jacques - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

HOUT-28. FIRST-LINE TEMOZOLOMIDE VS PCV FOR LOW GRADE GLIOMAS: A 11 YEARS REAL-WORLD DATA FROM CHUM, UNIVERSITY CENTER

Carole Lambert - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Low-grade gliomas

Temozolomide

INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS

Al Musella - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

N/A

ACTR-50. PRESERVATION OF NEUROCOGNITIVE FUNCTION & PATIENT-REPORTED SYMPTOMS WITH HIPPOCAMPAL AVOIDANCE (HA) DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: LONG-TERM RESULTS OF NRG ONCOLOGY CC001

Vijayananda Kundapur - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Brain metastasis

Memantine

HOUT-14. PROGNOSTIC IMPACT OF FIRST PSEUDOPROGRESSION ON MRI IN GLIOBLASTOMA, AN 11 YEARS EXPERIENCE FROM A CANADIAN UNIVERSITY CENTER

Carole Lambert - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

ACTR-12. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

John Langlands - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Dianhydrogalactitol

GENE-50. SWI/SNF COMPLEX HETEROGENEITY RELATES WITH POLYPHENOTYPIC DIFFERENTIATION, PROGNOSIS AND IMMUNE RESPONSE IN RHABDOID TUMORS

Steve Potter - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Rhabdoid predisposition syndrome

N/A

DRES-10. TEMOZOLOMIDE-ASSOCIATED HYPERMUTATION DETECTED WITH A GENE PANEL SIGNATURE IMPROVES IMMUNE RESPONSE IN GLIOBLASTOMA

Paul Daniel - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High-Grade Gliomas

Temozolomide

INNV-34. PATTERNS OF FAILURE AND DEVELOPMENT OF A NOVEL PROGNOSTIC SCORING SYSTEM IN ELDERLY PATIENTS WITH GLIOBLASTOMA – FOLLOW UP ON 10 YEAR ANALYSIS OF THE BC CANCER AGENCY POPULATION

Jonathan Zeng - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

NIMG-25. LESION-NETWORK ANALYSIS TO IDENTIFY PREFERENTIALLY-ENGAGED NETWORKS IN EPILEPTOGENIC TUMORS

Alireza Mansouri - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CBMT-37. OSMR CONTROLS CELLULAR RESPIRATION AND RESISTANCE TO THERAPY

Ahmad Sharanek - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain cancer

Temozolomide

ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402

Alan Hartford - Society for Neuro-Oncology (SNO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anaplastic oligodendroglial tumors

N/A

Copyright © 2026. QuantiNova All rights reserved